AUTHOR=Mohammed Omima S. , Attia Hany G. , Mohamed Bassim M. S. A. , Elbaset Marawan A. , Fayed Hany M. TITLE=Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches JOURNAL=Journal of Pharmacy & Pharmaceutical Sciences VOLUME=26 YEAR=2023 URL=https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences/articles/10.3389/jpps.2023.11808 DOI=10.3389/jpps.2023.11808 ISSN=1482-1826 ABSTRACT=

Long-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposing current FDA-approved drugs targeting etiological molecular factors involved in developing liver fibrosis. In parallel, investigations also focus on experimental small molecules with evidence to hinder or reverse the fibrosis. Natural compounds, immunological, and genetic approaches have shown significant encouraging effects. This review summarizes the efficacy and safety of current under-investigation antifibrosis medications targeting various molecular targets, as well as the properties of antifibrosis medications, mainly in phase II and III clinical trials.